CONCENTRAID
LOE ApproachingNDANASALSOLUTION
Approved
Dec 1990
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 5h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
CONCENTRAID is a nasal solution small molecule approved in 1990 by Ferring Pharmaceuticals. The specific indication and mechanism of action are not disclosed in available data. This product represents a mature, established nasal therapeutic with over three decades of clinical use.
LOE Approaching
With LOE approaching and zero linked job openings, the brand team is likely operating in maintenance/wind-down mode with minimal commercial expansion headcount.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
CONCENTRAID represents a declining-stage product with zero active job openings, signaling limited hiring and career momentum. Professionals seeking stability in a mature asset may find value, but growth-oriented careers should look elsewhere within the Ferring portfolio.
Brand ManagerField Sales Representative
Worked on CONCENTRAID at Ferring Pharmaceuticals? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.